For example, only 21.1% of the recurrent KIAA1549-BRAF fusion in pilocytic astrocytoma and 24.4% of ERG-TMPRSS2 in prostate adenocarcinoma led to neoantigens (Fig. 4c). This evidence concerns the gene TMPRSS2 and pilocytic astrocytoma.